✦ LIBER ✦

S1064 Certolizumab Pegol Effectiveness in Crohn's Disease Patients with Secondary Failure to Infliximab Is Independent of Infliximab Dosing: Results from the WELCOME Study

✍ Scribed by Maria T. Abreu; Severine Vermeire; Paul J. Rutgeerts; Thomas A. Ullman; Douglas C. Wolf; William J. Sandborn

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S1058 Certolizumab Pegol Improves Health

✍ Brian G. Feagan; William J. Sandborn; Douglas C. Wolf; Krassimir Mitchev; Corinn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 156 KB

S1030 Predictors of Response and Remissi

✍ William J. Sandborn; Maria T. Abreu; Geert R. D'Haens; Jean-Frederic Colombel; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 142 KB

9 ASSESSMENT OF CERTOLIZUMAB PEGOL IN TH

✍ S. Vermeire; M.T. Abreu; G. D'Haens; J.F. Colombe; K. Mitchev; A. Raedler; R.N. 📂 Article 📅 2008 🏛 Oxford University Press ⚖ 91 KB

494 Efficacy and Safety of Certolizumab

✍ Severine Vermeire; Maria T. Abreu; Geert D'Haens; Jean-Frédéric Colombel; Krassi 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 104 KB

S1035 Certolizumab Pegol is Effective at

✍ Stefan Schreiber; Ian C. Lawrance; Ole O. Thomsen; Stephen B. Hanauer; Ralph Blo 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 80 KB

143 Welcome: A Randomized, Double-Blind,

✍ William J. Sandborn; Severine Vermeire; Geert R. D'Haens; Jean-Frederic Colombel 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 102 KB